아질런트 테크놀로지스(A) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요🔔 구독
시가총액
$39.1B
미드캡
P/E
27.8
적정 수준
배당수익률
0.74%
52주 위치
58%
저점 +28% · 고점 -14%
애널리스트
매수
C+
Fundamental health
vs. Diagnostics & Research
수익성 ⓘ
Top 26%
성장 ⓘ
Top 73%
밸류에이션 ⓘ
Top 53%
재무 안정 ⓘ
Top 48%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 28원. Over the past 5년, it usually traded around 30원. On the cheaper side versus its own history.
Pricy doesn't mean bad — it means expectations are already baked in.
🔬 A specialty analytical instruments company that supplies global life science, diagnostics, and applied analysis equipment, reagents, and software solutions. Spun off from its former parent company in 1999 and headquartered in Santa Clara, California, it is a key pillar of a global analytical instruments group that provides a wide range of analytical instruments, consumable reagents, and services to the pharmaceutical, biotechnology, food, environmental, and clinical diagnostics fields.
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
🟢
Current diagnosis · 2026-07-24
Uptrend zone
Current price $138.57 above the midline ($133.54). Normal upward flow. Above the Ichimoku cloud (bullish).
MACD (12 · 26 · 9)Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
🟢
Current diagnosis · 2026-07-24
Bullish momentum holding
MACD 1.932 > Signal 1.669 in positive zone + Hist positive (+0.263). Trend in progress.
RSI(14) · Stochastics %K(14)Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
🟢
Current diagnosis · 2026-07-24
Bullish zone
RSI 61.3 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 80.1.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
🎯
Is it attractive at this price?
🎯
Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Sales·Vs. Cash Flow, In line with peers on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵Vs. EarningsCheap
🏢Vs. AssetsMid-range
🧾Vs. SalesCheap
💧Vs. Cash FlowCheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
27.83x
✓ Cheap
My positionMid-range
Low rangeAverageHigh range
Diagnostics & Research median 35.22x · Around the industry average
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
20.99x
✓ Cheap
My positionMid-range
Low rangeAverageHigh range
Diagnostics & Research median 22.77x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
5.49x
✓ Fair
My positionMid-range
Low rangeAverageHigh range
Diagnostics & Research median 3.37x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
5.41x
✓ Cheap
My positionMid-range
Low rangeAverageHigh range
Diagnostics & Research 대형주 median 5.41x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
21.01x
✓ Cheap
My positionMid-range
Low rangeAverageHigh range
Diagnostics & Research median 22.23x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
36.00x
✓ Fair
My positionMid-range
Low rangeAverageHigh range
Diagnostics & Research median 29.34x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$159.33 vs. current price +15.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Diagnostics & Research
👥
Who owns it?
⚠️
Ownership flow shows some pressure
Insider modest net selling -0.2% · Institutional modest net selling -0.5% · Short interest light 1.9%
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-0.2%
Insiders net selling
🏦 Institutions (funds & investors)
-0.5%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions92.5%
Institution-led, stable structure
Healthcare 대형주 Median 91.9%
🧑💼 Insiders0.3%
Low, common among large-caps
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated)7.1%
Everyone excluding institutions and insiders
InstitutionsInsidersRetail (est.)
📉 Short-selling metrics
Short ratio
1.9%
Low — limited short-side pressure
Healthcare 대형주 Median 3.6%
Past 90 days Little change
Short interest days to cover
2.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding282.2M주
Float (tradable shares)281.5M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
Leveraged, inverse, and covered call ETFs based on the underlying asset
24 derivative ETFs based on A (Leverage 8 · Inverse 8 · Covered Call 8)
These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.
ℹ️ What is a Derivative ETF?
These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.
⚠️ Caution: Long-Term Holding
Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.
📈Leverage8ETFs that move 2-3x with A (high volatility)